Skip to main content

Clinerion is now part of Citeline

| News

Clinerion is now part of Citeline


Clinerion has been integrated into New York-based company Citeline. Clinerion plans to expand its portfolio with Citeline’s complementary opportunities with regard to drug development acceleration. Clinerion’s headquarters are to remain in Basel.

Clinerion’s CEO Barış Erdoğan has officially announced that the company is now part of Citeline, a leader in clinical trials. The company based in New York, which formerly operated as Pharma Intelligence, merged with Norstella from the US state of Pennsylvania at the end of 2022. This means that the Norstella Group now comprises five companies: Evaluate, MMIT, Panalgo, The Dedham Group, and Citeline.

The new pharmaceutical technology company with more than 1,600 employees across the world is now one of the world’s largest providers of pharma information solutions on the market. According to a press release from Norstella, it is currently valued at 5 billion US dollars. It aims to enable smooth access to life-saving therapies for those with illnesses by accompanying life science companies throughout the entire drug development process.

Clinerion’s headquarters remain in Basel

According to a personal message from Clinerion’s CEO, its integration into Citeline provides the opportunity to access tools and services that each supplement the other’s, thus expanding the product portfolio. Furthermore, Clinerion will gain access to specialists and expertise along the entire process chain from clinical intelligence, planning, development, and studies. This is why the merger with Citeline and the Norstella Group is “excellent news” for partners and customers. Clinerion’s headquarters will remain in Basel.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

biGENIUS receives 2 million euros for new cloud product

Software company biGENIUS, based in the Basel Area, has secured financing of 2 million euros. This funding was granted following...
Read More

Opterion Health secures investment of 6.5 million Swiss francs

Opterion Health has raised a total of 6.5 million Swiss francs as part of a financing round. The company, which...
Read More

TOLREMO receives 39 million US dollars in investments

TOLREMO Therapeutics has concluded a series A funding round with 39 million US dollars. The biotech company based in Basel...
Read More

Mazars opens tenth Swiss office in Basel

Mazars is now also present in Basel with a subsidiary as of September 1. This is the tenth Swiss location...
Read More

Medtech in Switzerland – bringing together traditional skills and hightech industry

How the intersection of traditional and novel skillsets in the Jura area is propelling Switzerland into a new era of...
Read More

Fondation Botnar supporting further research into pediatric health

The Basel-based Botnar Research Centre for Child Health has received a further donation of 50 million Swiss francs from the...
Read More

Do you have a question? We'd like to hear from you.